Suppr超能文献

普拉德-威利综合征患者的骨密度降低:与肥胖受试者的比较。

Decreased bone mineral density in Prader-Willi syndrome: comparison with obese subjects.

作者信息

Butler M G, Haber L, Mernaugh R, Carlson M G, Price R, Feurer I D

机构信息

Section of Medical Genetics and Molecular Medicine, Children's Mercy Hospitals and Clinics and University of Missouri-Kansas City School of Medicine, Kansas City, Missouri 64108, USA.

出版信息

Am J Med Genet. 2001 Oct 15;103(3):216-22.

Abstract

Bone density, anthropometric data, and markers of bone turnover were collected on 21 subjects diagnosed with Prader-Willi syndrome (PWS) and compared with 9 subjects with obesity of unknown cause. In addition, urinary N-telopeptide levels were obtained in all subjects. N-telopeptides are the peptide fragments of type I collagen, the major bone matrix material. During periods of active bone degradation or high bone turnover, high levels of N-telopeptides are excreted in the urine. However, no significant difference was detected in the urinary N-telopeptide levels when corrected for creatinine excretion (raw or transformed data) between our subjects with obesity or PWS and the observed effect size of the between-group difference was small. Although N-telopeptide levels were higher but not significantly different in the subjects with PWS compared with obese controls, the subjects with PWS had significantly decreased total bone and spine mineral density and total bone mineral content (all P < 0.001). No differences in N-telopeptide levels or bone mineral density were observed between subjects with PWS and chromosome 15q deletion or maternal disomy. Thus, decreased bone mineral density in subjects with PWS may relate to the lack of depositing bone mineral during growth when bones are becoming more dense (e.g., during adolescence), possibly because of decreased production of sex or growth hormones and/or long-standing hypotonia. It may not be caused by loss, or active degradation, of bone matrix measurable by the methods described in this study further supporting the possible need for hormone therapy during adolescence.

摘要

收集了21名被诊断患有普拉德-威利综合征(PWS)的受试者的骨密度、人体测量数据和骨转换标志物,并与9名病因不明的肥胖受试者进行了比较。此外,还获取了所有受试者的尿N-端肽水平。N-端肽是I型胶原蛋白(主要的骨基质材料)的肽片段。在活跃的骨降解或高骨转换期间,高水平的N-端肽会通过尿液排出。然而,在根据肌酐排泄量校正(原始数据或转换后的数据)后,我们的肥胖或PWS受试者的尿N-端肽水平未检测到显著差异,且组间差异的观察效应大小较小。尽管与肥胖对照组相比,PWS受试者的N-端肽水平较高但无显著差异,但PWS受试者的总骨密度和脊柱骨密度以及总骨矿物质含量均显著降低(所有P<0.001)。在PWS受试者与15号染色体q缺失或母源二体的受试者之间,未观察到N-端肽水平或骨矿物质密度的差异。因此,PWS受试者骨矿物质密度降低可能与生长过程中(如青春期)骨骼密度增加时骨矿物质沉积不足有关,这可能是由于性激素或生长激素分泌减少和/或长期肌张力低下所致。它可能不是由本研究中描述的方法可测量的骨基质丢失或活跃降解引起的,这进一步支持了青春期可能需要激素治疗的观点。

相似文献

3
Metabolic syndrome in adult patients with Prader-Willi syndrome.成年普拉德-威利综合征患者的代谢综合征。
Nutr Metab Cardiovasc Dis. 2013 Nov;23(11):1134-40. doi: 10.1016/j.numecd.2012.11.006. Epub 2012 Dec 7.

引用本文的文献

3
High levels of LIGHT/TNFSF14 in patients with Prader-Willi syndrome.普拉德-威利综合征患者体内高水平的 LIGHT/TNFSF14。
J Endocrinol Invest. 2023 Sep;46(9):1901-1909. doi: 10.1007/s40618-023-02050-2. Epub 2023 Mar 14.
5
Genetic conditions of short stature: A review of three classic examples.遗传因素导致的身材矮小:三个经典案例回顾。
Front Endocrinol (Lausanne). 2022 Oct 21;13:1011960. doi: 10.3389/fendo.2022.1011960. eCollection 2022.
7
Irisin and Secondary Osteoporosis in Humans.鸢尾素与人类继发性骨质疏松症。
Int J Mol Sci. 2022 Jan 8;23(2):690. doi: 10.3390/ijms23020690.

本文引用的文献

1
Prader-Willi Syndrome: Clinical and Genetic Findings.普拉德-威利综合征:临床与遗传学发现。
Endocrinologist. 2000 Jul;10(4 Suppl 1):3S-16S. doi: 10.1097/00019616-200010041-00002.
3
Prader-Willi syndrome.普拉德-威利综合征
J Med Genet. 1997 Nov;34(11):917-23. doi: 10.1136/jmg.34.11.917.
4
Update on primary osteoporosis.原发性骨质疏松症的最新进展。
Mayo Clin Proc. 1997 Oct;72(10):943-9. doi: 10.1016/S0025-6196(11)63367-3.
7
Prader-Willi syndrome.普拉德-威利综合征
Curr Probl Pediatr. 1984 Jan;14(1):1-55. doi: 10.1016/0045-9380(84)90043-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验